Anti-dense fine speckled 70 (anti-DFS70) antibodies have been reported to be more prevalent in healthy individuals (HI) than in patients with autoimmune diseases including systemic lupus erythematosus (SLE). However, subsequent studies have yielded inconsistent findings. The reliability of anti-DFS70 antibodies as exclusionary markers for SLE remains uncertain and warrants further investigation.
Methods
Sixteen studies investigating 6092 subjects (2427 SLE patients and 3665 healthy individuals) were included in the analysis. A meta-analysis was conducted to evaluate and compare the sensitivity, specificity, and diagnostic odds ratio (DOR) of anti-DFS70 antibodies for determining their utility in excluding SLE in the general population.
Results
In SLE patients, the prevalence of anti-DFS70 antibodies was 10.1% (244/2427; 95% CI: 5.7–14.5%), which was not significantly higher than that of HI, at 5.8% (212/3665; 95% CI: 2.9–8.7%). The pooled sensitivities, specificities, and DOR of anti-DFS70 antibodies for the exclusion of SLE were 0.10 (95% CI: 0.09–0.11), 0.94 (95% CI: 0.93–0.95), 1.04 (95% CI: 0.59–1.85), respectively. The area under the summary receiver operating characteristic (SROC) curve was 0.58 (95% CI: 0.28–0.90), indicating that the test results of anti-DFS70 antibodies have similar distributions in SLE patients and HI. Regarding monospecific anti-DFS70 antibodies in SLE, three studies involving 385 patients with SLE and 648 healthy individuals found these antibodies in 0.8% (3 out of 385) of SLE patients, compared to 6.6% (43 out of 648) of healthy individuals. The corresponding DOR for excluding an SLE diagnosis was 4.00 (95% CI: 1.39–11.46).
Conclusions
While the present study corroborates findings that the frequency of anti-DFS70 antibodies is slightly higher in SLE patients (10.1%, 244 out of 2427), the lack of statistical significance underscores the need for more comprehensive studies to draw definitive conclusions for the exclusion of SLE.
BarberMRWFalasinnuTRamsey-GoldmanR, et al.The global epidemiology of SLE: narrowing the knowledge gaps. Rheumatology2023; 62(Suppl 1): i4–i9. https://doi.org/10.1093/rheumatology/keac610
2.
GuMChengQWangX, et al.The impact of SLE on health-related quality of life assessed with SF-36: a systemic review and meta-analysis. Lupus2019; 28: 371–382. https://doi.org/10.1177/0961203319828519
GergianakiIGarantziotisPAdamichouC, et al.High comorbidity burden in patients with SLE: data from the community-based lupus registry of Crete. J Clin Med2021; 10: 998. https://doi.org/10.3390/jcm10050998
5.
KuhnABonsmannGAndersHJ, et al.The diagnosis and treatment of systemic lupus erythematosus. Dtsch Arztebl Int2015; 112: 423–432. https://doi.org/10.3238/arztebl.2015.0423
6.
PigaMTseliosKViveirosL, et al.Clinical patterns of disease: from early systemic lupus erythematosus to late-onset disease. Best Pract Res Clin Rheumatol2023; 37: 101938. https://doi.org/10.1016/j.berh.2024.101938
7.
FanouriakisAKostopoulouMAlunnoA, et al.2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis2019; 78: 736–745. https://doi.org/10.1136/annrheumdis-2019-215089
MockenhauptLMDolscheid-PommerichRStoffel-WagnerB, et al.Autoantibodies to dense-fine-speckled 70 (DFS70) do not necessarily rule out connective tissue diseases. Semin Arthritis Rheum2022; 52: 151936. https://doi.org/10.1016/j.semarthrit.2021.12.006
10.
MarinGGCardielMHCornejoH, et al.Prevalence of antinuclear antibodies in 3 groups of healthy individuals: blood donors, hospital personnel, and relatives of patients with autoimmune diseases. J Clin Rheumatol2009; 15: 325–329. https://doi.org/10.1097/RHU.0b013e3181bb971b
11.
ChengCFShihMCLanTY, et al.Anti-DFS70 antibodies for differentiating systemic autoimmune rheumatic disease in patients with positive ANA tests: a systematic review and meta-analysis. Diagnostics2021; 11: 1592. https://doi.org/10.3390/diagnostics11091592
12.
MarizHASatoEIBarbosaSH, et al.Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum2011; 63: 191–200. https://doi.org/10.1002/art.30084
13.
Fitch-RogalskyCSteberWMahlerM, et al.Clinical and serological features of patients referred through a rheumatology triage system because of positive antinuclear antibodies. PLoS One2014; 9: e93812. https://doi.org/10.1371/journal.pone.0093812
14.
ConradKRöberNAndradeLE, et al.The clinical relevance of Anti-DFS70 autoantibodies. Clin Rev Allergy Immunol2017; 52: 202–216. https://doi.org/10.1007/s12016-016-8564-5
15.
MahlerMAndradeLECasianoCA, et al.Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness. Expet Rev Clin Immunol2019; 15: 241–250. https://doi.org/10.1080/1744666X.2019.1562903
OchsRLMuroYSiY, et al.Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol2000; 105: 1211–1220. https://doi.org/10.1067/mai.2000.107039
18.
BasuASanchezTWCasianoCA. DFS70/LEDGFp75: an enigmatic autoantigen at the interface between autoimmunity, AIDS, and cancer. Front Immunol2015; 6: 116. https://doi.org/10.3389/fimmu.2015.00116
19.
LeohLSMediavilla-VarelaMCasianoCA, et al.Autoantibodies to LEDGFp75/DFS70: natural autoantibodies or sensors of an augmented state of cellular oxidative stress. In: ConradKChanEKLFritzlerMJ (eds). From pathogenesis to therapy of autoimmune diseases. : PABST Science Publishers, 2009, vol 6, pp. 137–155.
BasuARojasHBanerjeeH, et al.Expression of the stress response oncoprotein LEDGF/p75 in human cancer: a study of 21 tumor types. PLoS One2012; 7: e30132. https://doi.org/10.1371/journal.pone.0030132
23.
LeitzJReuschenbachMLohreyC, et al.Oncogenic human papillomaviruses activate the tumor-associated lens epithelial-derived growth factor (LEDGF) gene. PLoS Pathog2014; 10: e1003957. https://doi.org/10.1371/journal.ppat.1003957
24.
WatanabeAKoderaMSugiuraK, et al.Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheumatol2004; 50: 892–900. https://doi.org/10.1002/art.20096
25.
DaiLLiJOrtegaR, et al.Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens. J Immunol Res2014; 2014: 827827. https://doi.org/10.1155/2014/827827
26.
SolomonDHKavanaughAJSchurPH, et al.Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum2002; 47: 434–444. https://doi.org/10.1002/art.10561
27.
Agmon-LevinNDamoiseauxJKallenbergC, et al.International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis2014; 73: 17–23. https://doi.org/10.1136/annrheumdis-2013-203863
28.
BentowCRosenblumRCorreiaP, et al.Development and multi-center evaluation of a novel immunoadsorption method for anti-DFS70 antibodies. Lupus2016; 25: 897–904. https://doi.org/10.1177/0961203316641773
29.
InfantinoMPregnolatoFBentowC, et al.Only monospecific anti-DFS70 antibodies aid in the exclusion of antinuclear antibody associated rheumatic diseases: an Italian experience. Clin Chem Lab Med2019; 57: 1764–1769. https://doi.org/10.1515/cclm-2019-0454
30.
MuroYSugiuraKMoritaY, et al.High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody-positive patients with autoimmune rheumatic disease. Lupus2008; 17: 171–176. https://doi.org/10.1177/0961203307086311
31.
HandonoKSusiantiHChilmiS, et al.The prevalence of anti-DFS70 antibodies in SLE and non-SLE. J Med Chem Sci2023; 6: 2716–2726.
32.
MahlerMParkerTPeeblesCL, et al.Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol2012; 39: 2104–2110. https://doi.org/10.3899/jrheum.120598
33.
MahlerMHanlyJGFritzlerMJ. Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmun Rev2012; 11: 642–645. https://doi.org/10.1016/j.autrev.2011.11.005
34.
MahlerMFritzlerMJ. The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. Clin Dev Immunol2012; 2012: 494356. https://doi.org/10.1155/2012/494356
35.
SeeligCABauerOSeeligHP. Autoantibodies against DFS70/LEDGF exclusion markers for systemic autoimmune rheumatic diseases (SARD). Clin Lab2016; 62: 499–517. https://doi.org/10.7754/clin.lab.2015.150905
36.
ShovmanOGilburdBChayatC, et al.Prevalence of anti-DFS70 antibodies in patients with and without systemic autoimmune rheumatic diseases. Clin Exp Rheumatol2018; 36: 121–126.
37.
JeongJKimDHParkG, et al.Clinical significance of anti-dense fine speckled 70 antibody in patients with fibromyalgia. Korean J Intern Med2019; 34: 426–433. https://doi.org/10.3904/kjim.2016.276
38.
NilssonACVossALillevangST. DFS70 autoantibodies are rare in healthy danish individuals but may still serve as a diagnostic aid. Scand J Immunol2015; 82: 547–548. https://doi.org/10.1111/sji.12366
39.
VerizhnikovaZRybakovaVAvdeevaA, et al.The significance of anti-DFS70 antibodies in healthy population as a marker of exclusion of systemic autoimmune diseases. Ann Rheum Dis2022; 81: 1846–1847. https://doi.org/10.1136/annrheumdis-2022-eular.4545
40.
HayashiNUtoKImanishiA, et al.Prevalence of anti-dense fine speckled 70 antibodies in healthy individuals and patients with antinuclear antibody-associated autoimmune rheumatic diseases in Japan. Medicine2021; 100: e24556. https://doi.org/10.1097/MD.0000000000024556
41.
SchmelingHMahlerMLevyDM, et al.Autoantibodies to dense fine speckles in pediatric diseases and controls. J Rheumatol2015; 42: 2419–2426. https://doi.org/10.3899/jrheum.150567
42.
ArteagaSUrregoTPeñarandaL, et al.Prevalence of anti-dfs70 antibodies in a Colombian cohort: a case-control study. Lupus Science & Medicine2017; 4: 125–126.
43.
PekerBOŞenerAGTarhanEF, et al.Investigation of anti-DFS70 antibody in patients with systemic autoimmune rheumatic diseases. Clin Rheumatol2019; 38: 3627–3633. https://doi.org/10.1007/s10067-019-04730-y
44.
DaiYLiEChenD, et al.Anti-DFS70 antibodies in systemic lupus erythematosus: prevalence in a large Chinese cohort and an unexpected association with anti-dsDNA antibodies by a long-term follow-up. Front Immunol2022; 13: 913714. https://doi.org/10.3389/fimmu.2022.913714
45.
PenevBVasilevGTodorovaEI, et al.First-degree relatives of patients with systemic lupus erythematosus: autoreactivity but not autoimmunity?Int J Rheum Dis2023; 26: 907–916. https://doi.org/10.1111/1756-185X.14669
46.
ChoiMYClarkeAESt PierreY, et al.The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus2017; 26: 1051–1059. https://doi.org/10.1177/0961203317692437
47.
DinseGEZhengBCoCA, et al.Anti-dense fine speckled 70 (DFS70) autoantibodies: correlates and increasing prevalence in the United States. Front Immunol2023; 14: 1186439. https://doi.org/10.3389/fimmu.2023.1186439
48.
WhitingPFRutjesAWWestwoodME, et al.QUADAS-2 group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med2011; 155: 529–536. https://doi.org/10.7326/0003-4819-155-8-201110180-00009
49.
ZamoraJAbrairaVMurielA, et al.Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol2006; 6: 31. https://doi.org/10.1186/1471-2288-6-31
50.
PramanikB. Diagnosis of systemic lupus erythematosus in an unusual presentation: what a primary care physician should know. Curr Rheumatol Rev2014; 10: 81–86. https://doi.org/10.2174/1573397111999150128103237
AringerMJohnsonSR. Systemic lupus erythematosus classification and diagnosis, Rheum Dis Clin N Am, Systemic Lupus Erythematosus Classification and Diagnosis. Rheum Dis Clin North Am2021; 47: 501–511. https://doi.org/10.1016/j.rdc.2021.04.011
53.
AdamichouCNikolopoulosDGenitsaridiI, et al.In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment. Ann Rheum Dis2020; 79: 232–241. https://doi.org/10.1136/annrheumdis-2019-216155
54.
BruceINBuieJBlochL, et al.Lupus spectrum ambiguity has long-term negative implications for patients. Lupus Sci Med2023; 10: e000856. https://doi.org/10.1136/lupus-2022-000856
55.
AringerMCostenbaderKDaikhD, et al.European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis2019; 78: 1151–1159. https://doi.org/10.1136/annrheumdis-2018-214819
56.
ChengCFLanTYShihMC, et al.Monospecific anti-DFS70 antibodies are moderately helpful in excluding ANA-associated rheumatic disease in patients presenting with a dense fine speckled pattern - a systematic review and meta-analysis of diagnostic test accuracy. Autoimmun Rev2020; 19: 102637. https://doi.org/10.1016/j.autrev.2020.102637
57.
ZotovaLKotovaVKuznetsovZ. The role of Anti-DFS70 in the diagnosis of systemic autoimmune rheumatic diseases. Biologics2023; 3: 342–354. https://doi.org/10.3390/biologics3040019
58.
CorbacıoğluŞKAkselG. Receiver operating characteristic curve analysis in diagnostic accuracy studies: a guide to interpreting the area under the curve value. Turk J Emerg Med2023; 23: 195–198. https://doi.org/10.4103/tjem.tjem_182_23
59.
ŚwierkotJMadejMSzmyrkaM, et al.The risk of autoimmunity development following mRNA COVID-19 vaccination. Viruses2022; 14: 2655. https://doi.org/10.3390/v14122655
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
